N-(5-isopropyl-4-methyl-thiazol-2-yl)-acetamide | 90565-68-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(5-isopropyl-4-methyl-thiazol-2-yl)-acetamide
• 英文别名: N-(5-Isopropyl-4-methyl-thiazol-2-yl)-acetamid；N-(4-methyl-5-propan-2-yl-1,3-thiazol-2-yl)acetamide
• CAS: 90565-68-7
• 化学式: C₉H₁₄N₂OS
• mdl: MFCD00520377
• 分子量: 198.289
• InChiKey: HSMQANCESAIIRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
  申请人：Sun Chongqing

  公开号：US20080194625A1

  公开（公告）日：2008-08-14

  The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

  本发明提供了式I的化合物，其中取代基如本文所述。还提供了使用这些化合物治疗进食障碍、代谢障碍、肥胖症、认知障碍、神经系统疾病、疼痛障碍、炎症障碍、促进戒烟和治疗其他精神障碍的方法。还提供了含有这些化合物的药物组合物以及本发明化合物与其他治疗剂的药物组合物。
• SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS
  申请人：Mas Prio Josep

  公开号：US20090209528A1

  公开（公告）日：2009-08-20

  The present invention relates to substituted tetrahydroisoquinoline compounds of general formula (I), a process for their preparation, medicaments comprising said substituted tetrahydroisoquinoline compounds as well as the use of said substituted tetrahydroisoquinoline compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT 6 receptors.

  本发明涉及一般式(I)的取代四氢异喹啉化合物，其制备方法，包含所述取代四氢异喹啉化合物的药物以及利用所述取代四氢异喹啉化合物制备药物，特别适用于预防和/或治疗至少部分通过5-HT6受体介导的疾病或疾病的用途。
• NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA
  申请人：Astrazeneca AB

  公开号：EP3426652B1

  公开（公告）日：2021-12-01
• Inhibitors of Akt activity
  申请人：Lindsley W. Craig

  公开号：US20070149536A1

  公开（公告）日：2007-06-28

  The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
• COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONARY HYPERTENSION
  申请人：STC.UNM

  公开号：US20180110774A1

  公开（公告）日：2018-04-26

  Methods and composition for treating or preventing pulmonary hypertension are provided. In certain aspects, compounds that inhibit T H 17 cell maturation or activity, such as retinoic acid receptor-related orphan nuclear receptor (ROR) inhibitors, are used to for the treatment of pulmonary hypertension.